<HashMap><database>GEO</database><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE332586</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition</name><description>Bone sarcomas are rare and aggressive pediatric cancers with limited progress in targeted therapy development, partly due to the poor physiological relevance of conventional two-dimensional (2D) culture systems used for preclinical testing. To address this gap, we developed a standardized three-dimensional (3D) culture and drug-testing platform for Ewing sarcoma (ES) and osteosarcoma (OS) that more accurately recapitulates in vivo tumor biology. Notably, gene-expression analyses demonstrated that ES and OS spheroids transcriptionally converge toward patient tumor cell states, underscoring their physiological relevance for preclinical testing. Across 3D spheroids, bioprinted constructs, and patient-derived xenograft (PDX) cultures, we observed a consistent activation and dependency on the mevalonate pathway in ES. Leveraging this platform, we identified a selective therapeutic synergy between statins, which inhibit mevalonate pathway flux, and BCL-xL inhibitors—a vulnerability not detectable in 2D cultures. Importantly, this synergistic interaction was tumor-specific and absent in non-malignant fibroblasts, indicating a favorable therapeutic window. Together, these findings highlight the mevalonate pathway as a targetable metabolic dependency in ES and demonstrate how physiologically grounded 3D models can uncover clinically actionable treatment strategies that remain hidden in traditional 2D systems.</description><dates><publication>2026/05/21</publication></dates><accession>GSE332586</accession><cross_references><GSM>GSM9751080</GSM><GSM>GSM9751081</GSM><GSM>GSM9751082</GSM><GSM>GSM9751102</GSM><GSM>GSM9751103</GSM><GSM>GSM9751104</GSM><GSM>GSM9751105</GSM><GSM>GSM9751106</GSM><GSM>GSM9751107</GSM><GSM>GSM9751108</GSM><GSM>GSM9751109</GSM><GSM>GSM9751083</GSM><GSM>GSM9751084</GSM><GSM>GSM9751085</GSM><GSM>GSM9751086</GSM><GSM>GSM9751087</GSM><GSM>GSM9751088</GSM><GSM>GSM9751100</GSM><GSM>GSM9751089</GSM><GSM>GSM9751101</GSM><GSM>GSM9751090</GSM><GSM>GSM9751091</GSM><GSM>GSM9751092</GSM><GSM>GSM9751093</GSM><GSM>GSM9751113</GSM><GSM>GSM9751114</GSM><GSM>GSM9751115</GSM><GSM>GSM9751094</GSM><GSM>GSM9751095</GSM><GSM>GSM9751096</GSM><GSM>GSM9751097</GSM><GSM>GSM9751098</GSM><GSM>GSM9751110</GSM><GSM>GSM9751099</GSM><GSM>GSM9751111</GSM><GSM>GSM9751112</GSM><GPL>20301</GPL><GSE>332586</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>